Priming of cytotoxic T lymphocytes (CTLs) by dendritic cells (DCs
F or triggering CD8
ϩ cytotoxic T lymphocytes (CTLs), recognition of an antigenic peptide-MHC class I (MHC-I) complex with its CD8 molecules as well as T cell receptors (TCRs) is indispensable (1) (2) (3) (4) . In this recognition process, the TCRs bind to the antigenic peptide in conjunction with the ␣1␣2 domains of MHC-I, and CD8 recognizes the ␣3 region of MHC-I (5). Blocking of CD8 binding to MHC-I with soluble recombinant CD8 or anti-CD8 antibodies leads to the inactivation of CTLs (6, 7) . In particular, a lack of CD8 in mice prevents the development of CTLs (8) . Recent studies indicated several cooperative effects of CD8 molecules. Kinetic analysis in the TCR-MHC-I interaction phase suggested that CD8 molecules recognize MHC-I before TCRs, and thereby enhance the TCR-MHC-I association process (9) . Biosensor analysis involving MHC-I-conjugated luminescent semiconductor nanocrystals showed that CD8 molecules do not always necessarily associate with the relevant peptide-MHC-I complex (cognate MHC) for appropriate TCRs, but their association with irrelevant peptide-MHC-I complexes (noncognate MHCs) effectively induces the engagement of antigen-specific TCRs with the cognate MHC (10) . Therefore, access of CD8 first to cognate or noncognate MHC-I is the initial step of CD8 ϩ T cell triggering.
Leukocyte Ig-like receptors (LILR)B1 and LILRB2 (also referred to as ILT2/MIR-7 and ILT4/MIR-10) (11, 12) , expressed on various human lymphoid and myeloid cells including DCs, recognize a broad spectrum of human MHC-I expressed ubiquitously (13, 14) . Crystal structure analysis of LILRB1 complexed with HLA-A2 demonstrated that LILRB1 recognizes the ␣3 domain and ␤ 2 -microglobulin (␤ 2 m) of the MHC-I (15), whose amino acid sequences are more conserved among the HLA alleles than in the polymorphic ␣1-␣2 region. These recognition sites partially overlap the binding sites of CD8␣␣ homodimer to HLA-A2 (5) . Related to the close recognition sites of CD8␣␣ and LILRB1, surface plasmon resonance (SPR) analysis involving recombinant HLA, LILRB1/ LILRB2, and CD8␣␣ verified that LILRB1 as well as LILRB2 competes with CD8␣␣ in binding to HLA molecules (16) . These results suggest a dynamic relation among LILRB1/B2, CD8, and MHC-I, although their possible interplay in physiological and pathological contexts has not been examined.
Paired Ig-like receptor-B, or PIR-B (17, 18) , expressed on murine B cells and myeloid cells including DCs but not on T cells or NK cells (18) (19) (20) , is considered to be a close relative to or ortholog for human LILRB1/B2 (21), based on similarities in such as its syntenic chromosomal location, molecular structure and inhibitory signaling, and ability to bind to a wide variety of H-2 molecules (21) as well as to human HLA-G (22) and HLA-B27 (23) . Principally, like LILRB1/B2, PIR-B is considered to play an indispensable role in immune regulation by recruiting SH2 domain-containing tyrosine phosphatase-1 to its cytoplasmic immunoreceptor tyrosine-based inhibitory motifs (ITIMs) on its constitutive binding to the ligand MHC-I, because PIR-B-deficient (Pirb Ϫ/Ϫ ) mice exhibit various augmented immune responses due to hyperactivated B cells and myeloid cells (20, 24, 25) . Simultaneously, however, the above knowledge obtained on SPR analysis of the competition between LILRB1/B2 and CD8 in binding to a constant portion of MHC-I (16) predicts that a possible steric conflict between PIR-B and CD8 in binding to H-2 may also play a role in immune regulation such as modulation of CTL activity in mice. In this study, we show the occurrence of such interplay among PIR-B, CD8, and MHC-I at the interface between antigen-presenting DCs and antigen-specific T cells, namely the immunological synapse.
543-nm laser, significant FRET was observed on B6, but not on Pirb Ϫ/Ϫ , BMDCs (Fig. 1B) . Thus, our FRET analyses revealed that the cultured BMDCs (Fig. 1B) and freshly isolated splenic B220 ϩ B cells (Fig. S1 ) also exhibited PIR-B binding to MHC-I on the same cell membrane, suggesting that the PIR-B-MHC-I interaction primarily takes place in cis on these antigen-presenting cells (APCs) as well as on cultured mast cells described previously (25) .
We next paid closer attention to the PIR-B-MHC-I binding on DCs, particularly in the immunological synapse formation phase with CD8 ϩ T cells. We first examined a possible trans interaction between PIR-B on DCs and MHC-I on CD8 ϩ T cells by confocal microscopic and FRET analyses. We prepared ovalbumin (OVA) peptide-loaded BMDCs from B2m Ϫ/Ϫ B6 mice and CD8 ϩ T cells from MHC-I-restricted, OVA-specific TCR transgenic (OT-I) mice. When the MHC-I-less BMDCs were cocultured with the OVA-specific CD8 ϩ T cells, the interface between the cells reproducibly exhibited a merged fluorescence profile for PIR and MHC-I showing the colocalization of PIR on BMDCs and MHC-I on T cells (Fig. 1C) , suggesting a substantial trans interaction for PIR-B-MHC-I, and possibly between PIR-A-MHC-I, but to a lesser extent, at the immunological synapse. To confirm the trans binding of PIR-B to MHC-I, we performed FRET analysis combined with an acceptor photobleaching technique. Significant FRET from the PIR-associated fluorophore on BMDCs to the MHC-I-associated fluorophore on T cells (FRET efficiency % ϭ 24.8 Ϯ 17.6, mean Ϯ SD., n ϭ 6) ( Fig. 1D Upper and Lower Left) was attenuated upon acceptor photobleaching of the MHC-I-associated fluorophore (Fig. 1D Left) , strongly suggesting the occurrence of trans binding of PIR-B on BMDCs to MHC-I on T cells. We also examined lateral movement of PIR-B on the DC membrane after formation of the immunological synapse, and found that PIR-B is roughly localized at the peripheral supramolecular activation complex (SMAC) at the mature immunological synapse (Fig. S2) . Collectively, these results indicate that PIR-B principally binds to MHC-I on the same DC membrane (in cis), and that can bind to MHC-I in trans on CD8 ϩ T cells at the immunological synapse, where PIR-B becomes localized at the peripheral SMAC upon synapse maturation. Given that PIR-B primarily binds to MHC-I in cis on BMDCs, we were interested in determining whether such constitutive association might be sterically inhibitory as to the access of CD8 molecules on T cells, because the relatively nonpolymorphic domain ␣3 of MHC-I on APCs or on target cells is the target for CD8 molecules. We investigated the MHC-I-restricted antigen presentation capacity of Pirb Ϫ/Ϫ BMDCs pulsed with OVA by coculturing them with OT-I cells in vitro. We found that the OT-I cells showed significantly enhanced proliferation compared to ones cocultured with B6 BMDCs (Fig. 2A) . The enhanced proliferation was accompanied by enhanced interleukin (IL)-2 and interferon (IFN)-␥ production by OT-I cells stimulated by Pirb Ϫ/Ϫ BMDCs ( Fig. 2 B and C). Although efficient uptake of antigens by DCs often enhances CTL activity (29) , the uptake of OVA by Pirb Ϫ/Ϫ BMDCs was comparable to that by wild-type BMDCs (20) . To exclude the possibility that the enhanced OT-I proliferation was merely due to an increased amount of OVA peptide-loaded H-2 molecules, we measured the expression level of OVA peptide-loaded H-2K b on BMDCs by flow cytometry. We verified that the antigen processing and presentation by Pirb Ϫ/Ϫ BMDCs were not impaired, as comparable expression of OVA 257-264 peptide (SIINFEKL) in conjunction with H-2K b (H-2K b /OVAp), which is the OT-I TCR ligand, was detected with specific monoclonal antibody (mAb) 25-D1.16 (30) on OVA-pulsed Pirb Ϫ/Ϫ and B6 BMDCs (Fig. 2D ). Enhanced antigen presentation to OT-I CD8 ϩ T cells by Pirb Ϫ/Ϫ BMDCs was MHC-I pathway-specific, as the proliferation of OVA-specific CD4 ϩ T cells (OT-II T cells) was reduced when Pirb Ϫ/Ϫ BMDCs were cocultured with OT-II cells (Fig. 2E ), in accordance with the previous observations for reduced MHC class II and CD80/86 molecules on Pirb Ϫ/Ϫ BMDCs (20) .
Enhanced Antitumor Effect Induced by Adoptive Transfer of Pirb ؊/؊
BMDCs. To further confirm the enhanced ability of Pirb Ϫ/Ϫ BMDCs as to CD8 ϩ T cell activation, we next tested the in vivo ability of Pirb Ϫ/Ϫ BMDCs to prime tumor-specific CTLs. Pirb Ϫ/Ϫ and B6 BMDCs were pulsed ex vivo with OVA, and then adoptively transferred to naïve B6 mice intravenously to evoke OVA-specific T cells. Seven days after the immunization by DC transfer, splenocytes were harvested and stimulated with x-ray-irradiated OVAexpressing E.G7 tumor cells, and then tumor-specific CTL generation was assessed by the means of a standard 51 Cr-release assay with E.G7 cells as the target. It was found that the killing of E.G7 cells was more effective for splenocytes from mice that had been immunized with Pirb Ϫ/Ϫ BMDCs compared to ones immunized with B6 BMDCs (Fig. 3A) .
Activation of tumor-specific CTLs by Pirb Ϫ/Ϫ BMDCs was further tested through tumor challenge experiments. Naïve B6 mice were twice immunized with OVA-pulsed Pirb Ϫ/Ϫ or B6 BMDCs into the left footpad. Seven days after the second immunization, the mice were s.c. inoculated with E.G7 cells into the left rear leg. The mice immunized with Pirb Ϫ/Ϫ BMDCs showed enhanced tumor rejection compared to those immunized with B6 BMDCs (Fig. 3B ).
These results demonstrate that Pirb Ϫ/Ϫ BMDCs induce efficient activation of tumor-specific CTLs in vivo.
Enhanced Rejection of H-Y-Incompatible Skin Grafts in Pirb
CTL activation induced by DCs is often evaluated by means of graft rejection. Grafts from male mice transplanted onto syngeneic female mice will be rejected in an MHC-I-restricted manner (31) . This rejection is caused by the incompatibility of the male-specific H-Y antigen, a well-known minor histocompatibility antigen (31) . In this case, recipient DCs pick up and present the H-Y antigen on MHC-I to activate CTLs. When tail skin grafts from male B6 mice were transplanted, female Pirb Ϫ/Ϫ mice showed accelerated graft rejection [mean survival time (MST) Ϯ SEM ϭ 25.7 Ϯ 2.3 days] compared to female B6 mice (MST Ϯ SEM ϭ 33.4 Ϯ 3.0 days), the difference being significant (P ϭ 0.0367) (Fig. 4A, closed symbols) . On allogeneic transplantation of tail skin grafts derived from BALB/cϫB6 F1 mice onto Pirb Ϫ/Ϫ and B6 mice, there was no significant difference in graft rejection (Fig. 4A, open symbols) . On H-Y-incompatible transplantation, CD69 ϩ activated CTLs were significantly increased in the spleens of recipient Pirb Ϫ/Ϫ mice at 14 days after the transplantation (Fig. 4B) . Infiltration of inflammatory cells into the skin grafts was analyzed at 21 days after the transplantation. Skin grafts transplanted onto both Pirb Ϫ/Ϫ and B6 mice exhibited infiltration of inflammatory cells (Fig. S3 a-h) . In particular, significantly increased numbers of infiltrated CD8 ϩ CTLs and CD11c ϩ DCs were found in the skin grafts transplanted onto Pirb Ϫ/Ϫ mice (Fig. 4C) . These results suggest that resident DCs in Pirb Ϫ/Ϫ mice also induce enhanced CTL activation as assessed by the rejection of syngeneic male skin grafts.
Modulated Cytokine Production and Costimulatory Molecule Expression
Do Not Explain the Enhanced CTL Activity in PIR-B Deficiency. What is the mechanism underlying enhanced CTL activation by Pirb Ϫ/Ϫ DCs? Possible scenarios include modulated production of cytokines, altered expression of costimulatory molecules, and changes in events at the immunological synapse. In particular, it is well known that DCs augment CTL activity through their cytokines and costimulatory molecules (32) . However, our analyses of the cytokine production by Pirb Ϫ/Ϫ BMDCs and the expression of costimulatory molecules did not support the possibility that their modulated cytokines or costimulatory molecules explain the enhanced CTL activity (see SI Results and Fig. S4 ).
Both the CTL Priming and Killing Steps Are Hampered in the Presence of
PIR-B on Transfected Cells. Next we examined the possibility of altered events in the immunological synapse at the Pirb Ϫ/Ϫ APCs-CD8 ϩ T cell interface. To this end, we tested the direct effect of PIR-B expression on either APCs or target cells on CTL activation. We generated PIR-B-expressing E.G7 cells (E.G7-Pirb) and used them as APCs and target cells for CTL stimulation. E.G7 cells express H-2 molecules sufficiently and CD80 at low level, but not PIR-B and CD86 (Fig. 5A) .
PIR-B transfection did not alter the expression profiles of H-2K
b /D b , CD80, and CD86 significantly. When CD8 ϩ T cells from OT-I mice were cocultured with mitomycin C-treated E.G7-Pirb, the proliferation of the OT-I T cells was reduced compared to that of ones cocultured with mock-transfected E.G7 cells (Fig. 5B) , indicating that PIR-B expression on APCs can inhibit CD8 ϩ T cell activation in the virtual absence of the cooperation of T cells with cytokines and costimulatory molecules on APCs.
To examine the effect of PIR-B on target cell killing, BMDCs from B6 mice were pulsed with OVA, and then transferred into B6 mice intravenously to prime OVA-specific CTLs in vivo. Seven days later, splenocytes were isolated from the BMDC-immunized mice and stimulated with irradiated E.G7 or E.G7-Pirb cells in vitro. Five days later, the splenocytes were examined for their target killing ability using E.G7 or E.G7-Pirb cells as targets. As shown in Fig. 5C , with either the E.G7 or E.G7-Pirb target, the stimulatory effect of E.G7-Pirb was markedly lower than that of E.G7, as was expected from the experiment shown in Fig. 5B . In addition, the lytic activity against E.G7-Pirb targets was also lower than that against E.G7 targets, although the magnitude of the lowering was less significant than that in the stimulatory phase. Collectively, these results indicate that both the CTL priming and killing steps are hampered by PIR-B expression on APCs and target cells, respectively, suggesting an inadequate CTL activity for efficient priming at the APC-CD8 ϩ T cell interface.
Competition Between PIR-B and CD8 for MHC-I Can Regulate CTL Triggering. Because the enhanced antigen presentation by Pirb Ϫ/Ϫ DCs was MHC-I-specific (see Fig. 2E ), it seems reasonable to speculate that efficient priming of CTLs could be affected by the cis interaction between PIR-B and MHC-I (see Fig. 1B ) or by the cis to trans transition of PIR-B binding to MHC-I followed by lateral translocation to peripheral SMAC (see Fig. 1 C and D and Fig. S2 ) or both. However, it has been demonstrated that MHC-I expressed on T cells is not required for the in vitro activation of naïve OT-I CD8 ϩ T cells, and that MHC-I-negative T cells can be activated by multivalent TCR engagement (33) . Therefore, trans binding itself may not play an indispensable role in T cell priming, thus highlighting a potential role of cis binding on APCs in the regulation of T cell activation.
To obtain clues as to the significance of PIR-B-MHC-I binding in the regulation of CTL priming, we performed structural modeling on PIR-B and H-2K b with the modeling program PDFAMS (34), using the data obtained from the crystal structure of LILRB1 complexed with HLA-A2 (Protein Data Bank ID: 1P7Q). Our structural model predicted that PIR-B would recognize the ␣3-domain and ␤ 2 m, which are closely located and partially overlap with the CD8␣␣-binding region, suggesting that PIR-B can compete with CD8 molecules in binding to MHC-I (Fig. 6A) , as was shown previously on SPR analysis of LILRB1 binding to HLA-A2 (16) . Because PIR-B is not expressed on resting CD8 ϩ T cells or activated CTLs (18), the above prediction could be physiologically important in the situation where PIR-B expressed on DCs as well as on target cells for CTLs binds to MHC-I in cis, and this cis-interacting PIR-B might decrease the accessibility of CD8 molecules. To examine this possibility, we prepared the recombinant ectodomain of PIR-B (rPIR-B) and CD8␣␣ (rCD8␣␣), and analyzed by SPR whether molecular competition occurs between PIR-B and CD8 in binding to an H-2 molecule. When H-2K b was immobilized on a sensor chip, rPIR-B bound to H-2K b at higher affinity (K d ϭ 9.7 M) than rCD8␣␣ (K d ϭ 34.0 M) (Fig. 6B) . Next, we examined the binding response to H-2K b by injecting increasing concentrations of rCD8␣␣ with or without a fixed, nearly saturating concentration (30.4 M) of rPIR-B (Fig. 6C Left) . The difference between the responses with and without rPIR-B decreased as the concentration of CD8␣␣ increased (Fig. 6C Right) , indicating that PIR-B and CD8␣␣ share binding sites on H-2K b , which is consistent with the competitive binding of LILRB1, a PIR-B ortholog, and CD8 to HLA (16) . Thus, our SPR data support the notion that PIR-B can compete with CD8␣␣ in binding to MHC-I, which is at least one of the critical factors for regulation of CD8 ϩ T cell triggering by PIR-B on DCs, both in vitro and in vivo.
Discussion
In this study, we have shown that PIR-B on DCs can regulate CTL triggering by competing with CD8 molecules in binding to MHC-I. A lack of the cis binding between PIR-B and MHC-I on Pirb Ϫ/Ϫ DCs could be one of the mechanisms for the enhanced CTL activity. At the same time, we do not exclude involvement of other mechanisms in the enhanced CTL triggering, such as unidentified soluble factors or cell-bound molecules functioning at or near the immunological synapse in the absence of PIR-B. Thus far, our attempts to demonstrate directly the inhibition of CD8 accessibility to MHC-I by rPIR-B have been unsuccessful, mainly due to the unstable nature of the rPIR-B ectodomain in solution, which yields very little of the recombinant protein. Nonetheless, our present study proposes a novel role of PIR-B, i.e., direct regulation of CD8 ϩ T cell activation through sterical impediment of the accessibility of CD8 molecules. Thus, PIR-B might be considered as a bifunctional MHC-I receptor for immune regulation, based on (i) signalmediated, direct control of B cells and myeloid cells via its cytoplasmic ITIMs (35) (36) (37) , as was proposed for the regulatory role of LILRB1/B2 (11, 12, 23, (38) (39) (40) (41) (42) , and (ii) indirect, steric inhibition of CD8 ϩ T cell priming via its ectodomain. On the wild-type DC surface, we observed cis binding between PIR-B and H-2K b /D b (Fig. 1B) , with the K d being 9.7 M for H-2K b (Fig. 6B) . On the other hand, the K d of CD8␣␣ as to H-2K b was 34.0 M (Fig. 6B) , which is a more dissociable value than that of PIR-B-MHC-I, suggesting that the recognition of H-2K b by CD8 molecules requires excess energy to remove PIR-B already bound to H-2K b . Therefore, an additional mechanism is necessary for swift dissociation of PIR-B from cis-binding MHC-I when CD8 molecules need to recognize the MHC-I on DCs. This is probably achieved through an unidentified event at the immunological synapse. At the interface between DCs and CD8 ϩ T cells, we demonstrated the occurrence of trans binding of PIR on DCs to MHC-I on OT-I CD8 ϩ T cells (Fig. 1 C and D) . Therefore, it is conceivable that PIR-B can bind to MHC-I in both cis and trans manners, and when CD8 ϩ T cells come close, PIR-B may preferentially bind to MHC-I in a trans manner, thereby making it easy for CD8 molecules to recognize MHC-I on DCs. After the initial cis to trans transition of PIR-B binding to MHC-I, PIR-B would be translocated into peripheral SMAC (Fig. S2) , where it no longer directly influences the CD8/TCR function on the central SMAC. This scenario needs to be examined through more detailed analysis of PIR-B movement and signaling in immunological synapses. What is the rationale for this proposed, novel function of PIR-B in physiological and pathological settings? In this study, we have shown the significance of PIR-B in graft survival and tumor rejection. On wild-type DCs, the cis interaction of PIR-B and MHC-I could also be important as a threshold for blocking excess CTL activity that would be harmful for the host and lead to development of autoimmune diseases. Our notion that PIR expression is up-regulated during DC maturation (Fig. S5C ) may imply the existence of physiological regulation of PIR-B expression during DC activation, such as in an inflammatory environment, that does not to trigger CTL exceedingly. It is also possible that this competition may serve to suppress or eliminate the chance of self-reactive CD8 ϩ T cells being elicited, as thymic DCs also express PIR-B on their surface (19) . In addition, the cis interaction of PIR-B and MHC-I possibly protects DCs from attack by CTLs, as DCs express antigenic MHC-I, which is also recognized by CTLs in the effector phase, while completing the mission to activate the CTLs. Further investigations are required to confirm the possible significance of the PIR-B function in health and disease. Exploitation of this novel, sterical regulatory mechanism for CTL triggering would be beneficial for the treatment of various immune disorders involving excess CD8 ϩ T cell activation such as inflammatory, autoimmune, and transplantation-related diseases, and for augmenting immune cell attack against malignancies and viral infections.
Materials and Methods
For the FRET analysis, anti-PIR-A/B (6C1), anti-␤2m (S19.8), and anti-SIRP1␣ (P84) were labeled with Alexa546, and anti-H-2K b /D b (28 -8-6 ) was labeled with Alexa647, by using an Alexa Fluor 546 or 647 monoclonal antibody labeling kit (Invitrogen). FRET analysis and image processing were performed as described previously (25) (see SI Materials and Methods). Statistical differences were calculated by using Student's t test or two-way ANOVA. For the graft survival and tumor challenge experiments, statistical differences were calculated by using the log-rank test. P Ͻ 0.05 was considered significant. Other methods are detailed in SI Materials and Methods and elsewhere (43, 44) .
